Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical Cancer
By
Alberto Farolfi
Chiara Casadei
Emanuela Scarpi
Eleonora Paoletti
Caterina Gianni
Michela Palleschi
Nicola Gentili
Marita Mariotti
Sara Testoni
Giandomenico Di Menna
Francesca Rusconi
Alice Andalò
Olga Serra
Filippo Merloni
Marianna Sirico
Roberta Maltoni
Lorenzo Cecconetto
Samanta Sarti
Antonino Musolino
July 14, 2026
Clinical Scorecard: Selection of Bevacizumab and Platinum-Based Therapy in Patients with Advanced Cervical Cancer Treated with Pembrolizumab
At a Glance
Category Detail
Condition Advanced Cervical Cancer Key Mechanisms Tumor vasculature targeting, immune checkpoint blockade, and tumor cell death promotion. Target Population Adult patients with advanced, recurrent, or metastatic cervical cancer. Care Setting Oncology clinics utilizing systemic therapies.
Key Highlights
Induction chemotherapy with carboplatin and paclitaxel improves progression-free survival and overall survival. Bevacizumab is established as standard of care, improving overall survival in advanced cervical cancer. Pembrolizumab combined with platinum-based chemotherapy significantly prolongs progression-free survival and overall survival. Guideline-Based Recommendations
Diagnosis
Diagnosis of cervical cancer confirmed by ICD-10-CM code C53. Management
First-line systemic treatment includes pembrolizumab, paclitaxel, and a platinum agent (cisplatin or carboplatin), with or without bevacizumab. Monitoring & Follow-up
Monitor for severe adverse events, including gastrointestinal fistula and thromboembolic complications. Risks
Increased risk of severe adverse events with bevacizumab. Patient & Prescribing Data
Adult patients diagnosed with advanced cervical cancer receiving first-line systemic treatment.
Treatment regimens may vary based on physician discretion regarding platinum agent choice and bevacizumab use.
Clinical Best Practices
Utilize standardized treatment protocols for advanced cervical cancer. Consider patient-specific factors when selecting platinum agents and adding bevacizumab. Related Resources & Content
